Leading Pharmaceutical Innovation - Gassmann, Oliver;Schuhmacher, Alexander;Zedtwitz, Max von
42,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 6-10 Tagen
payback
21 °P sammeln
  • Broschiertes Buch

This book investigates and highlights the most critical challenges the pharmaceutical industry faces in an increasingly competitive environment of inflationary R&D investments and tightening cost control pressures. The authors present three sources of pharmaceutical innovation: new management methods in the drug development pipeline; new technologies as enablers for cutting-edge R&D; and new forms of cooperation and internationalization, such as open innovation in the early phases of R&D. New models and methods are illustrated with cases from Europe, the US, and Asia. This third fully revised…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
This book investigates and highlights the most critical challenges the pharmaceutical industry faces in an increasingly competitive environment of inflationary R&D investments and tightening cost control pressures. The authors present three sources of pharmaceutical innovation: new management methods in the drug development pipeline; new technologies as enablers for cutting-edge R&D; and new forms of cooperation and internationalization, such as open innovation in the early phases of R&D. New models and methods are illustrated with cases from Europe, the US, and Asia. This third fully revised edition was expanded to reflect the latest updates in open and collaborative innovation, the greater strategic importance of venture capital and early-stage investments, and the new range of emerging technologies now being put to use in pharmaceutical innovation.
Autorenporträt
Prof. Dr. Oliver Gassmann is professor of technology management at the University of St. Gallen (Switzerland), and managing director of the Institute of Technology Management. After completing his PhD in 1996, he was head of corporate research at Schindler. He published over 400 papers in leading international management journals. In 2014, he was awarded the Scholary Impact Award by the Journal of Management, and in 2015 with the Citation Excellence Award of the Emerald Group. He also serves as a founder and advisor on several boards. Prof. Dr. Alexander Schuhmacher is professor at Reutlingen University (Germany). He teaches in business management and medical science. He officiates as Senator of Reutlingen University and he also serves as managing director of the Knowledge Foundation @ Reutlingen University. He worked for 14 years in various R&D positions in the pharmaceutical industry. As member of Nycomed's senior R&D management team, he headed the Strategic Planning & Business Support function and co-headed the R&D integration team following the merger of Nycomed and ALTANA Pharma. Prof. Dr. Max von Zedtwitz is professor at Kaunas University of Technology (Lithuania), and director of the GLORAD Center for Global R&D and Innovation. Previously he was a professor at Tsinghua, Peking University, Skoltech, and IMD, and a vice president at PRTM. In 2009 he was recognized by IAMOT as one of the fifty most influential innovation scholars worldwide. A frequent public speaker, he has appeared on television, and has been cited in the Economist, China Daily, the South China Morning Post and the New York Times. Dr. Gerrit Reepmeyer is co-founder & COO of Guardhat Inc., a startup based in Detroit (USA). Prior to that, he held various executive leadership positions in industrial and technology companies. He started his career in management consulting with McKinsey & Company. He has a PhD degree from the University of St. Gallen and was a research scholar at Columbia University in New York. He co-authored several books and publications on technology management, and he is co-inventor of five patents.
Rezensionen
From the reviews:

"This book examines the international pharmaceutical industry with special emphasis on the current and emerging research methodologies ... . What distinguishes this book from others on the same subject is its emphasis on empirical findings (53 figures, 20 tables) and an exceptionally good, if short, discussion of various research technologies ... . The six-page glossary of industry terms, when used with its decent index, is a particular joy. ... recommend this offering to prospective managers and researchers in this industry ... ." (Robert R. Rothberg, Journal of Product Innovation Management, Vol. 22, 2005)

From the reviews of the second edition:

"Leading Pharmaceutical Innovation, Gassmann and colleagues describe the current status of the pharmaceutical industry ... . This book comprises seven chapters, where each could be seen as a review of the addressed topic. This helps with understanding the complexity of the challenges the pharmaceutical industry is facing, in comparison to the automotive industry or with respect to marketing problems ... . book provides most valuable insight into the pharmaceutical industry from an 'outsiders' perspective." (Sandrine Shepard and Thomas Wilckens, R&D Management, Vol. 40 (5), November, 2010)